In the early 1990s, pharmaceutical companies began to produce recombinant synthesized factor products, which now prevent nearly all forms of disease transmission during replacement therapy.
A principios da década dos 1990, as compañías farmacéuticas empezaron a producir factores de coagulación sintéticos recombinantes, o que agora impide case todas as formas de transmisión de enfermidades durante as terapias con produtos sanguíneos.